Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (41): 7787-7790.doi: 10.3969/j.issn.2095-4344.2012.41.037

Previous Articles    

Transplantation of umbilical cord mononuclear cells for treatment of infantile spastic cerebral palsy

Xu Rong1, Liu Bo2, Duan Da2, Fan Meng-yao2, Liu Bin1, Teng Xiao-hua2, Zhao Zhen-yu2, Lu Ming2   

  1. 1Medical College of Hunan Normal University, Changsha 410006, Hunan Province, China
    2Department of Neurosurgery, Second Affiliated Hospital of Hunan Normal University,the163 Hospital of Chinese PLA, Changsha 410003, Hunan Province, China
  • Received:2012-01-09 Revised:2012-01-29 Online:2012-10-07 Published:2013-04-09
  • Contact: Lu Ming, Professor, Chief physician, Department of Neurosurgery, Second Affiliated Hospital of Hunan Normal University,the163 Hospital of Chinese PLA, Changsha 410003, Hunan Province, China lming163@yahoo.com.cn
  • About author:Xu Rong★, Master, Physician, Medical College of Hunan Normal University, Changsha 410006, Hunan Province, China xurong0706@163.com

PDF

470

Abstract:

BACKGROUND: A large number of studies have demonstrated that umbilical cord mesenchymal stem cells cultured in vitro can express the surface markers of neurons and glial cells under induction and exhibit replacing and repairing effects for nervous system disease.
OBJECTIVE: To study the therapeutic effect and safety of transplantation of human umbilical cord blood mononuclear cells in treatment of infantile spastic cerebral palsy.
METHODS: Umbilical cord blood was harvested from full term deliveries scheduled for cesarean section and anti-coagulated with heparin. Umbilical cord blood mononuclear cells were isolated by lymphocyte separation medium, purified by Nash differential adhesion, and then injected into subarachnoid cavity of 30 infantile patients with spastic cerebral palsy.
RESULTS AND CONCLUSION: Compared with prior to treatment, the muscle spastic and joint range of motion significantly improved after treatment (P < 0.05). There were no adverse events and complications after transplantation and during follow-up period.

CLC Number: